A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer
NCT00102895
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
25
Enrollment
INDUSTRY
Sponsor class
Stopped
See Detailed Description
Conditions
Breast Neoplasms
Neoplasm Metastasis
Interventions
DRUG:
CP-724,714
Sponsor
Pfizer